Read by QxMD icon Read

Lilly Oncology

José A Sacristán, Luís Lizan, Marta Comellas, Pilar Garrido, Cristina Avendaño, Juan J Cruz-Hernández, Javier Espinosa, Tatiana Dilla
INTRODUCTION: The purpose of this study was to explore the main factors explaining the relative weight of the different attributes that determine the value of oncologic treatments from the different perspectives of healthcare policy makers (HCPM), oncologists, patients and the general population in Spain. METHODS: Structured interviews were conducted to assess: (1) the importance of the attributes on treatment choice when comparing a new cancer drug with a standard cancer treatment; (2) the importance of survival, quality of life (QoL), costs and innovation in cancer; and (3) the most worrying side effects related to cancer drugs...
October 7, 2016: Advances in Therapy
William D Tap, Robin L Jones, Brian A Van Tine, Bartosz Chmielowski, Anthony D Elias, Douglas Adkins, Mark Agulnik, Matthew M Cooney, Michael B Livingston, Gregory Pennock, Meera R Hameed, Gaurav D Shah, Amy Qin, Ashwin Shahir, Damien M Cronier, Robert Ilaria, Ilaria Conti, Jan Cosaert, Gary K Schwartz
BACKGROUND: Treatment with doxorubicin is a present standard of care for patients with metastatic soft-tissue sarcoma and median overall survival for those treated is 12-16 months, but few, if any, novel treatments or chemotherapy combinations have been able to improve these poor outcomes. Olaratumab is a human antiplatelet-derived growth factor receptor α monoclonal antibody that has antitumour activity in human sarcoma xenografts. We aimed to assess the efficacy of olaratumab plus doxorubicin in patients with advanced or metastatic soft-tissue sarcoma...
July 30, 2016: Lancet
Wynn G Hunter, Ashley Hesson, J Kelly Davis, Christine Kirby, Lillie D Williamson, Jamison A Barnett, Peter A Ubel
BACKGROUND: Nearly one in three Americans are financially burdened by their medical expenses. To mitigate financial distress, experts recommend routine physician-patient cost conversations. However, the content and incidence of these conversations are unclear, and rigorous definitions are lacking. We sought to develop a novel set of cost conversation definitions, and determine the impact of definitional variation on cost conversation incidence in three clinical settings. METHODS: Retrospective, mixed-methods analysis of transcribed dialogue from 1,755 outpatient encounters for routine clinical management of breast cancer, rheumatoid arthritis, and depression, occurring between 2010-2014...
2016: BMC Health Services Research
Wynn G Hunter, Cecilia Z Zhang, Ashley Hesson, J Kelly Davis, Christine Kirby, Lillie D Williamson, Jamison A Barnett, Peter A Ubel
BACKGROUND: More than 1 in 4 Americans report difficulty paying medical bills. Cost-reducing strategies discussed during outpatient physician visits remain poorly characterized. OBJECTIVE: We sought to determine how often patients and physicians discuss health care costs during outpatient visits and what strategies, if any, they discussed to lower patient out-of-pocket costs. DESIGN: Retrospective analysis of dialogue from 1,755 outpatient visits in community-based practices nationwide from 2010 to 2014...
October 2016: Medical Decision Making: An International Journal of the Society for Medical Decision Making
Harry D Bear, Gong Tang, Priya Rastogi, Charles E Geyer, Qing Liu, André Robidoux, Luis Baez-Diaz, Adam M Brufsky, Rita S Mehta, Louis Fehrenbacher, James A Young, Francis M Senecal, Rakesh Gaur, Richard G Margolese, Paul T Adams, Howard M Gross, Joseph P Costantino, Soonmyung Paik, Sandra M Swain, Eleftherios P Mamounas, Norman Wolmark
BACKGROUND: NSABP B-40 was a 3 × 2 factorial trial testing whether adding capecitabine or gemcitabine to docetaxel followed by doxorubicin plus cyclophosphamide neoadjuvant chemotherapy would improve outcomes in women with operable, HER2-negative breast cancer and whether adding neoadjuvant plus adjuvant bevacizumab to neoadjuvant chemotherapy regimens would also improve outcomes. As reported previously, addition of neoadjuvant bevacizumab increased the proportion of patients achieving a pathological complete response, which was the primary endpoint...
September 2015: Lancet Oncology
J Yu, Y Gong, V Bar-Ad, T Giaddui, C Hu, E Gore, M Wheatley, J Witt, C Robinson, F Kong, J Bradley, J Galvin, Y Xiao
PURPOSE: Accurate contour delineation is crucial for radiotherapy. Atlas based automatic segmentation tools can be used to increase the efficiency of contour accuracy evaluation. This study aims to optimize technical parameters utilized in the tool by exploring the impact of library size and atlas number on the accuracy of cardiac contour evaluation. METHODS: Patient CT DICOMs from RTOG 0617 were used for this study. Five experienced physicians delineated the cardiac structures including pericardium, atria and ventricles following an atlas guideline...
June 2015: Medical Physics
Andrew X Zhu, Joon Oh Park, Baek-Yeol Ryoo, Chia-Jui Yen, Ronnie Poon, Davide Pastorelli, Jean-Frederic Blanc, Hyun Cheol Chung, Ari D Baron, Tulio Eduardo Flesch Pfiffer, Takuji Okusaka, Katerina Kubackova, Jorg Trojan, Javier Sastre, Ian Chau, Shao-Chun Chang, Paolo B Abada, Ling Yang, Jonathan D Schwartz, Masatoshi Kudo
BACKGROUND: VEGF and VEGF receptor-2-mediated angiogenesis contribute to hepatocellular carcinoma pathogenesis. Ramucirumab is a recombinant IgG1 monoclonal antibody and VEGF receptor-2 antagonist. We aimed to assess the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma following first-line therapy with sorafenib. METHODS: In this randomised, placebo-controlled, double-blind, multicentre, phase 3 trial (REACH), patients were enrolled from 154 centres in 27 countries...
July 2015: Lancet Oncology
Nick Thatcher, Fred R Hirsch, Alexander V Luft, Aleksandra Szczesna, Tudor E Ciuleanu, Mircea Dediu, Rodryg Ramlau, Rinat K Galiulin, Beatrix Bálint, György Losonczy, Andrzej Kazarnowicz, Keunchil Park, Christian Schumann, Martin Reck, Henrik Depenbrock, Shivani Nanda, Anamarija Kruljac-Letunic, Raffael Kurek, Luis Paz-Ares, Mark A Socinski
BACKGROUND: Necitumumab is a second-generation, recombinant, human immunoglobulin G1 EGFR antibody. In this study, we aimed to compare treatment with necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone in patients with previously untreated stage IV squamous non-small-cell lung cancer. METHODS: We did this open-label, randomised phase 3 study at 184 investigative sites in 26 countries. Patients aged 18 years or older with histologically or cytologically confirmed stage IV squamous non-small-cell lung cancer, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and adequate organ function and who had not received previous chemotherapy for their disease were eligible for inclusion...
July 2015: Lancet Oncology
Gitte Lee Mortensen, Lilli Lundby
INTRODUCTION: Anal cancer is a rare malignancy, but during the past three decades, its incidence has increased in both sexes. Approximately 90% of anal cancers are related to human papillomavirus infection. The primary treatment for anal cancer is radiotherapy or radio-chemotherapy. This quality of life (QoL) study aimed at obtaining in-depth knowledge about patients' experiences with anal cancer and its impact on their QoL. METHODS: A literature study identified topics for qualitative interviews with six anal cancer patients who had received oncological treatment and were without recurrent disease...
March 2015: Danish Medical Journal
Luis Paz-Ares, Jörg Mezger, Tudor E Ciuleanu, Jürgen R Fischer, Joachim von Pawel, Mariano Provencio, Andrzej Kazarnowicz, György Losonczy, Gilberto de Castro, Aleksandra Szczesna, Lucio Crino, Martin Reck, Rodryg Ramlau, Ernst Ulsperger, Christian Schumann, Jose Elias A Miziara, Álvaro E Lessa, Mircea Dediu, Beatrix Bálint, Henrik Depenbrock, Victoria Soldatenkova, Raffael Kurek, Fred R Hirsch, Nick Thatcher, Mark A Socinski
BACKGROUND: Necitumumab is a second-generation recombinant human immunoglobulin G1 EGFR monoclonal antibody that competitively inhibits ligand binding. We aimed to compare necitumumab plus pemetrexed and cisplatin with pemetrexed and cisplatin alone in patients with previously untreated, stage IV, non-squamous non-small-cell lung cancer (NSCLC). METHODS: We did this randomised, open-label, controlled phase 3 study at 103 sites in 20 countries. Patients aged 18 years or older, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and adequate organ function, were randomly assigned 1:1 to treatment with a block randomisation scheme (block size of four) via a telephone-based interactive voice-response system or interactive web-response system...
March 2015: Lancet Oncology
Cora N Sternberg, Iwona Skoneczna, J Martijn Kerst, Peter Albers, Sophie D Fossa, Mads Agerbaek, Herlinde Dumez, Maria de Santis, Christine Théodore, Michael G Leahy, John D Chester, Antony Verbaeys, Gedske Daugaard, Lori Wood, J Alfred Witjes, Ronald de Wit, Lionel Geoffrois, Lisa Sengelov, George Thalmann, Danielle Charpentier, Frédéric Rolland, Laurent Mignot, Santhanam Sundar, Paul Symonds, John Graham, Florence Joly, Sandrine Marreaud, Laurence Collette, Richard Sylvester
BACKGROUND: Patients with muscle-invasive urothelial carcinoma of the bladder have poor survival after cystectomy. The EORTC 30994 trial aimed to compare immediate versus deferred cisplatin-based combination chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder. METHODS: This intergroup, open-label, randomised, phase 3 trial recruited patients from hospitals across Europe and Canada. Eligible patients had histologically proven urothelial carcinoma of the bladder, pT3-pT4 disease or node positive (pN1-3) M0 disease after radical cystectomy and bilateral lymphadenectomy, with no evidence of any microscopic residual disease...
January 2015: Lancet Oncology
Lillie D Shockney
Over the last several decades, breast screening, diagnosis, and treatment have evolved. With that evolutionary process, so have the complexities of oncology care, especially from the perspective of more fragmented care occurring. The majority of breast care is outpatient based. The need for patient navigation has heightened as this fragmentation and financial issues set before the oncologist and the patient continue to occur and in many situations increase. Without effective navigation, breast patients can fall through the cracks and not get diagnosed as early as possible, or not receive all appropriate treatment they need...
January 2015: Breast Journal
Ali Amin Al Olama, Zsofia Kote-Jarai, Sonja I Berndt, David V Conti, Fredrick Schumacher, Ying Han, Sara Benlloch, Dennis J Hazelett, Zhaoming Wang, Ed Saunders, Daniel Leongamornlert, Sara Lindstrom, Sara Jugurnauth-Little, Tokhir Dadaev, Malgorzata Tymrakiewicz, Daniel O Stram, Kristin Rand, Peggy Wan, Alex Stram, Xin Sheng, Loreall C Pooler, Karen Park, Lucy Xia, Jonathan Tyrer, Laurence N Kolonel, Loic Le Marchand, Robert N Hoover, Mitchell J Machiela, Merideth Yeager, Laurie Burdette, Charles C Chung, Amy Hutchinson, Kai Yu, Chee Goh, Mahbubl Ahmed, Koveela Govindasami, Michelle Guy, Teuvo L J Tammela, Anssi Auvinen, Tiina Wahlfors, Johanna Schleutker, Tapio Visakorpi, Katri A Leinonen, Jianfeng Xu, Markus Aly, Jenny Donovan, Ruth C Travis, Tim J Key, Afshan Siddiq, Federico Canzian, Kay-Tee Khaw, Atsushi Takahashi, Michiaki Kubo, Paul Pharoah, Nora Pashayan, Maren Weischer, Borge G Nordestgaard, Sune F Nielsen, Peter Klarskov, Martin Andreas Røder, Peter Iversen, Stephen N Thibodeau, Shannon K McDonnell, Daniel J Schaid, Janet L Stanford, Suzanne Kolb, Sarah Holt, Beatrice Knudsen, Antonio Hurtado Coll, Susan M Gapstur, W Ryan Diver, Victoria L Stevens, Christiane Maier, Manuel Luedeke, Kathleen Herkommer, Antje E Rinckleb, Sara S Strom, Curtis Pettaway, Edward D Yeboah, Yao Tettey, Richard B Biritwum, Andrew A Adjei, Evelyn Tay, Ann Truelove, Shelley Niwa, Anand P Chokkalingam, Lisa Cannon-Albright, Cezary Cybulski, Dominika Wokołorczyk, Wojciech Kluźniak, Jong Park, Thomas Sellers, Hui-Yi Lin, William B Isaacs, Alan W Partin, Hermann Brenner, Aida Karina Dieffenbach, Christa Stegmaier, Constance Chen, Edward L Giovannucci, Jing Ma, Meir Stampfer, Kathryn L Penney, Lorelei Mucci, Esther M John, Sue A Ingles, Rick A Kittles, Adam B Murphy, Hardev Pandha, Agnieszka Michael, Andrzej M Kierzek, William Blot, Lisa B Signorello, Wei Zheng, Demetrius Albanes, Jarmo Virtamo, Stephanie Weinstein, Barbara Nemesure, John Carpten, Cristina Leske, Suh-Yuh Wu, Anselm Hennis, Adam S Kibel, Benjamin A Rybicki, Christine Neslund-Dudas, Ann W Hsing, Lisa Chu, Phyllis J Goodman, Eric A Klein, S Lilly Zheng, Jyotsna Batra, Judith Clements, Amanda Spurdle, Manuel R Teixeira, Paula Paulo, Sofia Maia, Chavdar Slavov, Radka Kaneva, Vanio Mitev, John S Witte, Graham Casey, Elizabeth M Gillanders, Daniella Seminara, Elio Riboli, Freddie C Hamdy, Gerhard A Coetzee, Qiyuan Li, Matthew L Freedman, David J Hunter, Kenneth Muir, Henrik Gronberg, David E Neal, Melissa Southey, Graham G Giles, Gianluca Severi, Michael B Cook, Hidewaki Nakagawa, Fredrik Wiklund, Peter Kraft, Stephen J Chanock, Brian E Henderson, Douglas F Easton, Rosalind A Eeles, Christopher A Haiman
Genome-wide association studies (GWAS) have identified 76 variants associated with prostate cancer risk predominantly in populations of European ancestry. To identify additional susceptibility loci for this common cancer, we conducted a meta-analysis of > 10 million SNPs in 43,303 prostate cancer cases and 43,737 controls from studies in populations of European, African, Japanese and Latino ancestry. Twenty-three new susceptibility loci were identified at association P < 5 × 10(-8); 15 variants were identified among men of European ancestry, 7 were identified in multi-ancestry analyses and 1 was associated with early-onset prostate cancer...
October 2014: Nature Genetics
Burt Zweigenhaft, Linda Bosserman, James T Kenney, Grant D Lawless, Thomas A Marsland, Craig K Deligdish, Douglas S Burgoyne, Kevin B Knopf, Douglas M Long, Patrick McKercher, Gary M Owens, John E Hennessy, James R Lang, Jennifer Malin, Leonard Natelson, Matthew C Palmgren, Jayson Slotnik, Lillie D Shockney, F Randy Vogenberg
The AVBCC Annual Meeting experiences exponential growth in attendance and participation as oncologists, payers, employers, managed care executives, patient advocates, and drug manufacturers convened in Hollywood, FL, on May 2-5, 2013, for the Third Annual Conference of the Association for Value-Based Cancer Care (AVBCC). The conference presented an all-inclusive open forum for stakeholder dialogue and integration across the cancer care continuum, facilitating an open dialogue among the various healthcare stakeholders to align their perspectives around the urgent need to address value in cancer care, costs, patient education, safety, outcomes, and quality...
July 2013: American Health & Drug Benefits
James Chih-Hsin Yang, Jin Hyoung Kang, Tony Mok, Myung-Ju Ahn, Vichien Srimuninnimit, Chia-Chi Lin, Dong-Wan Kim, Chun-Ming Tsai, Helen Barraclough, Sedat Altug, Mauro Orlando, Keunchil Park
BACKGROUND: In the Iressa Pan-ASia Study (IPASS), gefitinib claimed improved progression-free survival (PFS) versus carboplatin-paclitaxel in clinically selected lung cancer patients. The primary objective of this study was to assess the PFS of pemetrexed-cisplatin (PC) followed by gefitinib maintenance versus gefitinib monotherapy in an IPASS-like population. METHODS: In this open-label, randomised, phase 3 trial, eligible patients were ⩾18 years, chemonaïve, East Asian, light ex-smokers/never-smokers with advanced non-squamous non-small cell lung cancer, an Eastern Cooperative Oncology Group (ECOG) performance status 0-1 and unknown epidermal growth factor receptor (EGFR) mutation status who enrolled at 12 sites in Asia...
September 2014: European Journal of Cancer
Martha Aschenbrenner, Bruce Ham, Paula K Rauch, Zoraida Sambolin, Maya Silver, Lillie D Shockney
A roundtable presentation at the NCCN 19th Annual Conference focused on the child's experience when a parent has cancer and concluded that honest communication, appropriate to the child's age and temperament, is essential, and that oncology providers should institute programs that help families deal with the illness.
May 2014: Journal of the National Comprehensive Cancer Network: JNCCN
Lilly Aung, Robert E J Howells, Kenneth C K Lim, Emma Hudson, Peter W Jones
OBJECTIVE: This study aimed to examine the existing methods of follow-up in women who have undergone treatment of early endometrial carcinoma in South Wales and to assess if they are appropriate. DESIGN: This study used a retrospective analysis of follow-up data. SETTING: This study was performed in the Virtual Gynaecological Oncology Centre, South Wales, United Kingdom. SAMPLE: This study sample is composed of 552 women...
March 2014: International Journal of Gynecological Cancer
Reik Löser, Ralf Bergmann, Maxim Frizler, Birgit Mosch, Lilli Dombrowski, Manuela Kuchar, Jörg Steinbach, Michael Gütschow, Jens Pietzsch
A fluorinated cathepsin inhibitor based on the azadipeptide nitrile chemotype was prepared and selected for positron emission tomography (PET) tracer development owing to its high affinity for the oncologically relevant cathepsins L, S, K and B. Labelling with fluorine-18 was accomplished in an efficient and reliable two-step, one-pot radiosynthesis by using 2-[(18) F]fluoroethylnosylate as a prosthetic agent. The pharmacokinetic properties of the resulting radiotracer compound were studied in vitro, ex vivo and in vivo in normal rats by radiometabolite analysis and small-animal positron emission tomography...
August 2013: ChemMedChem
Hossein-Ardeschir Ghofrani, Nicholas Morrell, Marius Hoeper, Shelley Shapiro, Debbie Quinn, Oliver Schmidt
SESSION TYPE: DVT/PE/Pulmonary Hypertension Posters IPRESENTED ON: Wednesday, October 24, 2012 at 01:30 PM - 02:30 PMPURPOSE: PAH is a life-threatening disease with poor prognosis. Imatinib inhibits the PDGF signaling pathway, which appears important in PAH pathogenesis.METHODS: 59 patients symptomatic on approved PAH-specific therapies entered a 24-week, randomized, double-blind, placebo-controlled, pilot study (imatinib 200-400mg daily, n=28; placebo, n=31). 42 patients completed the 24-week study, and 22 entered an open-label extension (OLE) with imatinib...
October 1, 2012: Chest
Lillie D Shockney, Pamela J Haylock, Cynthia Cantril
OBJECTIVES: To review the development of a navigation program in a major US academic health care institution, and provide guidance for navigation programmatic development in other settings. DATA SOURCES: The Johns Hopkins Breast Center Steering Committee minutes, Hospital Cancer Registry; administrative data, and literature. CONCLUSION: Incorporating navigation services throughout the cancer continuum, from diagnosis to survivorship, provides guidance for patients with cancer...
May 2013: Seminars in Oncology Nursing
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"